Biovista Uses Artificial Intelligence to Address COVID-19
Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.
Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced on Aug. 25 by bioscience firm Biovista. The firm identified Cablivi and Atozet as particularly suited to target specific aspects of blood clotting and inflammation in the context of COVID-19.
This follows a mechanistic rationale Biovista released in March, suggesting Aprotinin and Irbesartan as potential COVID-19 treatments to reduce the effects of the cytokine storm, as well as helping reduce viral loads.
For more information, click here.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
The 8 Market Access Performance Metrics You Should Be Tracking
March 25th 2025This guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.
